Abstract
Novel compounds have been developed that (in many cases) inhibit cholinesterases and concomitantly interact with at least one further pharmacological target, such as 5-HT3 or H3 receptors. But also enzymes like monoamine oxidase and the serotonin transporter have been targeted. Hybrid molecules can also incorporate antioxidant or neuronal Ca2+- channel-blocking structures.
Keywords: Hybrid molecules, Multiple ligands, AChE inhibitors, Serotonin transporter (SERT), monoamine oxidase (MAO), lipoic acid, 5-HT3 receptor, Ca2+-channel blockers
Mini-Reviews in Medicinal Chemistry
Title: Recent Advances in the Development of Hybrid Molecules/Designed Multiple Compounds with Antiamnesic Properties
Volume: 7 Issue: 3
Author(s): Michael Decker
Affiliation:
Keywords: Hybrid molecules, Multiple ligands, AChE inhibitors, Serotonin transporter (SERT), monoamine oxidase (MAO), lipoic acid, 5-HT3 receptor, Ca2+-channel blockers
Abstract: Novel compounds have been developed that (in many cases) inhibit cholinesterases and concomitantly interact with at least one further pharmacological target, such as 5-HT3 or H3 receptors. But also enzymes like monoamine oxidase and the serotonin transporter have been targeted. Hybrid molecules can also incorporate antioxidant or neuronal Ca2+- channel-blocking structures.
Export Options
About this article
Cite this article as:
Decker Michael, Recent Advances in the Development of Hybrid Molecules/Designed Multiple Compounds with Antiamnesic Properties, Mini-Reviews in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/138955707780059817
DOI https://dx.doi.org/10.2174/138955707780059817 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Definition of Genes and Paths Involved in Alzheimers Disease: Using Gene Expression Profiles and Chemical Genetics at the Mouse Brain Level
Current Genomics Secondary Prevention of Ischemic Stroke
Current Drug Targets Characterization of the Early CNS Stress Biomarkers and Profiles Associated with Neuropsychiatric Diseases
Current Genomics The Vascular Component of Alzheimer`s Disease
Current Neurovascular Research Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets From Preclinical to Clinical Trials: An Update on Potential Therapies for Huntington’s Disease
Current Psychopharmacology Lipoic Acid: A Novel Therapeutic Approach for Multiple Sclerosis and Other Chronic Inflammatory Diseases of the CNS
Endocrine, Metabolic & Immune Disorders - Drug Targets The Neuropathology of Vascular Disease in the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS)
Current Alzheimer Research Serotonin 5-HT<sub>1A</sub> Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs
Current Pharmaceutical Design The Correlations between Postmortem Brain Pathologies and Cognitive Dysfunction in Aging and Alzheimer's Disease
Current Alzheimer Research Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease
Current Alzheimer Research “Virostatics” as a Potential New Class of HIV Drugs
Current Pharmaceutical Design Telomerase Therapeutics for Degenerative Diseases
Current Molecular Medicine Use of the Bradykinin Agonist, Cereport as a Pharmacological Means of Increasing Drug Delivery to the CNS
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Therapeutic Potential of N-Acetylcysteine for Wound Healing, Acute Bronchiolitis, and Congenital Heart Defects
Current Drug Metabolism Codon Usage Biases in Alzheimers Disease and Other Neurodegenerative Diseases
Protein & Peptide Letters Neurotoxicity of β-Amyloid Protein: Oligomerization, Channel Formation and Calcium Dyshomeostasis
Current Pharmaceutical Design Induction of Molecular Chaperones as a Therapeutic Strategy for the Polyglutamine Diseases
Current Pharmaceutical Biotechnology New Developments in Anti-Platelet Therapies Potential Use of CD39/Vascular ATP Diphosphohydrolase in Thrombotic Disorders
Current Drug Targets Huntingtons Disease: New Frontiers for Molecular and Cell Therapy
Current Drug Targets